Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07169825
Status
Recruiting
Apply to this trial

Conditions

  • Lu-177 PSMA

Eligibility Criteria

Sex
MALE
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lu-177 — DRUG
    Given by IV
  • SPECT — OTHER
    SPECT/CT

Study Details

To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.

Key Dates

Start date
Mar 30, 2026
Status verified
Mar 2026
Primary completion
Sep 1, 2026
Completion
Sep 1, 2028

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA

Primary Outcome Measure

safety and adverse events (AEs). [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Guofan Xu, MD
[email protected]
713-745-9017
Guofan Xu, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX